PortalPublikationenBaricitinib improves symptoms in patients with moderate-to-s...

Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials

Standard

Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials. / Reich, K; DeLozier, A M; Nunes, F P; Thyssen, J P; Eichenfield, L F; Wollenberg, A; Ross Terres, J A; Watts, S D; Chen, Y-F; Simpson, E L; Silverberg, J I.

in: J DERMATOL TREAT, Jahrgang 33, Nr. 3, 05.2022, S. 1521-1530 .

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Reich, K, DeLozier, AM, Nunes, FP, Thyssen, JP, Eichenfield, LF, Wollenberg, A, Ross Terres, JA, Watts, SD, Chen, Y-F, Simpson, EL & Silverberg, JI 2022, 'Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials', J DERMATOL TREAT, Jg. 33, Nr. 3, S. 1521-1530 . https://doi.org/10.1080/09546634.2020.1839008

APA

Reich, K., DeLozier, A. M., Nunes, F. P., Thyssen, J. P., Eichenfield, L. F., Wollenberg, A., Ross Terres, J. A., Watts, S. D., Chen, Y-F., Simpson, E. L., & Silverberg, J. I. (2022). Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials. J DERMATOL TREAT, 33(3), 1521-1530 . https://doi.org/10.1080/09546634.2020.1839008

Vancouver

Reich K, DeLozier AM, Nunes FP, Thyssen JP, Eichenfield LF, Wollenberg A et al. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials. J DERMATOL TREAT. 2022 Mai;33(3):1521-1530 . https://doi.org/10.1080/09546634.2020.1839008

Bibtex

@article{4845af59495d46309b653910af0f271e,
title = "Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials",
abstract = "BACKGROUND: Itch, skin pain, and sleep disturbance are burdensome symptoms in atopic dermatitis (AD) that negatively influence a patient's quality of life (QoL).OBJECTIVE: To evaluate the impact of baricitinib on patient-reported outcomes (PROs) in adult patients with moderate-to-severe AD, and explore the association between improvement in key signs and symptoms of AD with improvements in QoL and patient's assessment of disease severity.METHODS: Data were analyzed from two phase III monotherapy trials (BREEZE-AD1/BREEZE-AD2) in which patients were randomized 2:1:1:1 to once-daily placebo, baricitinib 1-mg, 2-mg, or 4-mg for 16 weeks and assessed using PRO measures.RESULTS: At week 16, baricitinib 4-mg and 2-mg significantly reduced itch severity (Itch Numeric Rating Scale (NRS) (BREEZE-AD1: percent change from baseline -36.6% and -29.4% vs. placebo (-12.0%), p≤.001 and p≤.05; BREEZE-AD2: -47.2% and -46.9% vs. placebo (-16.6%), p≤.001). Baricitinib significantly reduced SCORing AD (SCORAD) pruritus (4-mg in BREEZE-AD1 and 2-mg in BREEZE-AD2) and Patient Oriented Eczema Measure (POEM) itch (both doses). Improvements in skin pain severity and sleep disturbance were also observed. Improvements in AD symptoms showed higher correlations with patients' assessment of AD severity and QoL than improvements in skin inflammation.CONCLUSIONS: Baricitinib significantly improved symptoms in patients with moderate-to-severe AD.CLINICALTRIALS.GOV IDENTIFIERS: NCT03334396 (BREEZE-AD1) and NCT03334422 (BREEZE-AD2).",
author = "K Reich and DeLozier, {A M} and Nunes, {F P} and Thyssen, {J P} and Eichenfield, {L F} and A Wollenberg and {Ross Terres}, {J A} and Watts, {S D} and Y-F Chen and Simpson, {E L} and Silverberg, {J I}",
year = "2022",
month = may,
doi = "10.1080/09546634.2020.1839008",
language = "English",
volume = "33",
pages = "1521--1530 ",
journal = "J DERMATOL TREAT",
issn = "0954-6634",
publisher = "informa healthcare",
number = "3",

}

RIS

TY - JOUR

T1 - Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials

AU - Reich, K

AU - DeLozier, A M

AU - Nunes, F P

AU - Thyssen, J P

AU - Eichenfield, L F

AU - Wollenberg, A

AU - Ross Terres, J A

AU - Watts, S D

AU - Chen, Y-F

AU - Simpson, E L

AU - Silverberg, J I

PY - 2022/5

Y1 - 2022/5

N2 - BACKGROUND: Itch, skin pain, and sleep disturbance are burdensome symptoms in atopic dermatitis (AD) that negatively influence a patient's quality of life (QoL).OBJECTIVE: To evaluate the impact of baricitinib on patient-reported outcomes (PROs) in adult patients with moderate-to-severe AD, and explore the association between improvement in key signs and symptoms of AD with improvements in QoL and patient's assessment of disease severity.METHODS: Data were analyzed from two phase III monotherapy trials (BREEZE-AD1/BREEZE-AD2) in which patients were randomized 2:1:1:1 to once-daily placebo, baricitinib 1-mg, 2-mg, or 4-mg for 16 weeks and assessed using PRO measures.RESULTS: At week 16, baricitinib 4-mg and 2-mg significantly reduced itch severity (Itch Numeric Rating Scale (NRS) (BREEZE-AD1: percent change from baseline -36.6% and -29.4% vs. placebo (-12.0%), p≤.001 and p≤.05; BREEZE-AD2: -47.2% and -46.9% vs. placebo (-16.6%), p≤.001). Baricitinib significantly reduced SCORing AD (SCORAD) pruritus (4-mg in BREEZE-AD1 and 2-mg in BREEZE-AD2) and Patient Oriented Eczema Measure (POEM) itch (both doses). Improvements in skin pain severity and sleep disturbance were also observed. Improvements in AD symptoms showed higher correlations with patients' assessment of AD severity and QoL than improvements in skin inflammation.CONCLUSIONS: Baricitinib significantly improved symptoms in patients with moderate-to-severe AD.CLINICALTRIALS.GOV IDENTIFIERS: NCT03334396 (BREEZE-AD1) and NCT03334422 (BREEZE-AD2).

AB - BACKGROUND: Itch, skin pain, and sleep disturbance are burdensome symptoms in atopic dermatitis (AD) that negatively influence a patient's quality of life (QoL).OBJECTIVE: To evaluate the impact of baricitinib on patient-reported outcomes (PROs) in adult patients with moderate-to-severe AD, and explore the association between improvement in key signs and symptoms of AD with improvements in QoL and patient's assessment of disease severity.METHODS: Data were analyzed from two phase III monotherapy trials (BREEZE-AD1/BREEZE-AD2) in which patients were randomized 2:1:1:1 to once-daily placebo, baricitinib 1-mg, 2-mg, or 4-mg for 16 weeks and assessed using PRO measures.RESULTS: At week 16, baricitinib 4-mg and 2-mg significantly reduced itch severity (Itch Numeric Rating Scale (NRS) (BREEZE-AD1: percent change from baseline -36.6% and -29.4% vs. placebo (-12.0%), p≤.001 and p≤.05; BREEZE-AD2: -47.2% and -46.9% vs. placebo (-16.6%), p≤.001). Baricitinib significantly reduced SCORing AD (SCORAD) pruritus (4-mg in BREEZE-AD1 and 2-mg in BREEZE-AD2) and Patient Oriented Eczema Measure (POEM) itch (both doses). Improvements in skin pain severity and sleep disturbance were also observed. Improvements in AD symptoms showed higher correlations with patients' assessment of AD severity and QoL than improvements in skin inflammation.CONCLUSIONS: Baricitinib significantly improved symptoms in patients with moderate-to-severe AD.CLINICALTRIALS.GOV IDENTIFIERS: NCT03334396 (BREEZE-AD1) and NCT03334422 (BREEZE-AD2).

U2 - 10.1080/09546634.2020.1839008

DO - 10.1080/09546634.2020.1839008

M3 - SCORING: Journal article

C2 - 33222559

VL - 33

SP - 1521

EP - 1530

JO - J DERMATOL TREAT

JF - J DERMATOL TREAT

SN - 0954-6634

IS - 3

ER -